<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35226748</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1945-7197</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>107</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical endocrinology and metabolism</Title>
          <ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Autoimmune Thyroid Disorders in Autoimmune Addison Disease.</ArticleTitle>
        <Pagination>
          <StartPage>e2331</StartPage>
          <EndPage>e2338</EndPage>
          <MedlinePgn>e2331-e2338</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1210/clinem/dgac089</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Autoimmune thyroid disease is the most common endocrine comorbidity in autoimmune Addison disease (AAD), but detailed investigations of prevalence and clinical course are lacking.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This work aimed to provide comprehensive epidemiological and clinical data on autoimmune thyroid disorders in AAD.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A nationwide registry-based study including 442 patients with AAD and autoimmune thyroid disease were identified through the Norwegian National Registry of Autoimmune Diseases.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 912 registered AAD patients, 442 (48%) were diagnosed with autoimmune thyroid disease. A total of 380 (42%) had autoimmune hypothyroidism. Of the 203 with available thyroid function tests at time of diagnosis, 20% had overt hypothyroidism, 73% had subclinical hypothyroidism, and 7% had thyroid levels in the normal range. Negative thyroid peroxidase antibodies was found in 32%. Ninety-eight percent were treated with levothyroxine, 5% with combination therapy with liothyronine or thyroid extracts, and 1% were observed without treatment. Seventy-eight patients (9%) were diagnosed with Graves disease (GD), of whom 16 (21%) were diagnosed with autoimmune hypothyroidism either before onset or after remission of GD. At the end of follow-up, 33% had normal thyroid hormone levels without antithyroid-drugs or levothyroxine treatment. The remaining had either active disease (5%), had undergone ablative treatment (41%), or had developed autoimmune hypothyroidism (21%).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The true prevalence of hypothyroidism in AAD is lower than reported in the current literature. Careful consideration of the indication to start thyroxin therapy is warranted. Long-term remission rates in GD patients with AAD are comparable to recent reports on long-term follow-up of patients without AAD.</AbstractText>
          <CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Meling Stokland</LastName>
            <ForeName>Ann-Elin</ForeName>
            <Initials>AE</Initials>
            <Identifier Source="ORCID">0000-0003-4496-615X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Stavanger University Hospital, 4011 Stavanger, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ueland</LastName>
            <ForeName>Grethe</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lima</LastName>
            <ForeName>Kari</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Akershus University Hospital, 1474 Nordbyhagen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grønning</LastName>
            <ForeName>Kaja</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Akershus University Hospital, 1474 Nordbyhagen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Finnes</LastName>
            <ForeName>Trine E</ForeName>
            <Initials>TE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Innlandet Hospital Trust, 2318 Hamar, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Oslo University Hospital, 0372 Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Svendsen</LastName>
            <ForeName>Margrethe</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Østfold Hospital, 1714 Grålum, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ewa Tomkowicz</LastName>
            <ForeName>Aneta</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Sørlandet Hospital Trust, 4615 Kristiansand, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Emblem Holte</LastName>
            <ForeName>Synnøve</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Sørlandet Hospital Trust 4838 Arendal, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Therese Sollid</LastName>
            <ForeName>Stina</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-8153-938X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Drammen Hospital, Vestre Viken Health Trust, 3004 Drammen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Debowska</LastName>
            <ForeName>Aleksandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Vestfold Hospital, 3103 Tønsberg, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singsås</LastName>
            <ForeName>Hallvard</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, St. Olavs Hospital, 7006 Trondheim, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Landsverk Rensvik</LastName>
            <ForeName>Marthe</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Ålesund Hospital, 6017 Ålesund, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lejon</LastName>
            <ForeName>Helle</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Internal Medicine, University Hospital of North Norway, 9019 Tromsø, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sørmo</LastName>
            <ForeName>Dag-Erik</ForeName>
            <Initials>DE</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medicine, Levanger Hospital, 7600 Levanger, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Svare</LastName>
            <ForeName>Anders</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medicine, Nord-Trøndelag Hospital Trust, 7800 Namsos, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blika</LastName>
            <ForeName>Sigrid</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medicine, Telemark Hospital, 3719 Skien, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Milova</LastName>
            <ForeName>Petya</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medicine, Telemark Hospital, 3719 Skien, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Korsgaard</LastName>
            <ForeName>Elin</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medicine, Vestre Viken Hospital Trust, 3612 Kongsberg, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Husby</LastName>
            <ForeName>Øystein</ForeName>
            <Initials>Ø</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Bærum Sykehus, 1346 Gjettum, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Breivik</LastName>
            <ForeName>Lars</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jørgensen</LastName>
            <ForeName>Anders P</ForeName>
            <Initials>AP</Initials>
            <Identifier Source="ORCID">0000-0002-1246-9194</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Oslo University Hospital, 0372 Oslo, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sverre Husebye</LastName>
            <ForeName>Eystein</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-7886-2976</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>K. G. Jebsen Center for Autoimmune Disorders, University of Bergen, 5021 Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Endocrinol Metab</MedlineTA>
        <NlmUniqueID>0375362</NlmUniqueID>
        <ISSNLinking>0021-972X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013963">Thyroid Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q51BO43MG4</RegistryNumber>
          <NameOfSubstance UI="D013974">Thyroxine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C562768">Hypothyroidism, Autoimmune</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000224" MajorTopicYN="Y">Addison Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006111" MajorTopicYN="Y">Graves Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050031" MajorTopicYN="Y">Hashimoto Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007037" MajorTopicYN="Y">Hypothyroidism</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013963" MajorTopicYN="N">Thyroid Hormones</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013967" MajorTopicYN="N">Thyroiditis, Autoimmune</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013974" MajorTopicYN="N">Thyroxine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Graves disease</Keyword>
        <Keyword MajorTopicYN="N">autoimmune Addison disease</Keyword>
        <Keyword MajorTopicYN="N">autoimmune hypothyroidism</Keyword>
        <Keyword MajorTopicYN="N">autoimmune polyendocrine syndromes</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>17</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35226748</ArticleId>
        <ArticleId IdType="pmc">PMC9113809</ArticleId>
        <ArticleId IdType="doi">10.1210/clinem/dgac089</ArticleId>
        <ArticleId IdType="pii">6539869</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal insufficiency. Lancet 2021;397(10274):613-629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33484633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dalin F, Nordling Eriksson G, Dahlqvist P, et al. . 
Clinical and immunological characteristics of autoimmune Addison disease: a nationwide Swedish multicenter study. J Clin Endocrinol Metab. 2017;102(2):379-389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27870550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Erichsen MM, Løvås K, Skinningsrud B, et al. . 
Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009;94(12):4882-4890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19858318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Betterle C, Scarpa R, Garelli S, et al. . 
Addison’s disease: a survey on 633 patients in Padova. Eur J Endocrinol. 2013;169(6):773-784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24014553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Samuels MH. Effects of variations in physiological cortisol levels on thyrotropin secretion in subjects with adrenal insufficiency: a clinical research center study. J Clin Endocrinol Metab. 2000;85(4):1388-1393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10770171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Topliss DJ, White EL, Stockigt JR. Significance of thyrotropin excess in untreated primary adrenal insufficiency. J Clin Endocrinol Metab. 1980;50(1):52-56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6765953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saevik ÅB, Åkerman AK, Grønning K, et al. . 
Clues for early detection of autoimmune Addison’s disease—myths and realities. J Intern Med. 2018;283(2):190-199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29098731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Husebye ES, Allolio B, Arlt W, et al. . 
Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med. 2014;275(2):104-115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24330030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pearce SHS, Brabant G, Duntas LH, et al. . 
2013 ETA Guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215-228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3923601</ArticleId>
            <ArticleId IdType="pubmed">24783053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Oftedal BE, Wolff ASB, Bratland E, et al. . 
Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol. 2008;129(1):163-169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18708298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nedrebo BG, Holm PI, Uhlving S, et al. . 
Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol. 2002;147(5):583-589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12444889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carlé A, Laurberg P, Knudsen N, et al. . 
Thyroid peroxidase and thyroglobulin auto-antibodies in patients with newly diagnosed overt hypothyroidism. Autoimmunity. 2006;39(6):497-503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17060029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646-2655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12826640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schmidt M, Voell M, Rahlff I, et al. . 
Long-term follow-up of antithyroid peroxidase antibodies in patients with chronic autoimmune thyroiditis (Hashimoto’s thyroiditis) treated with levothyroxine. Thyroid. 2008;18(7):755-760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18631004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burgos N, Toloza FJK, Singh Ospina NM, et al. . 
Clinical outcomes after discontinuation of thyroid hormone replacement: a systematic review and meta-analysis. Thyroid. 2021;31(5):740-751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8110016</ArticleId>
            <ArticleId IdType="pubmed">33161885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bensing S, Hulting AL, Husebye ES, Kämpe O, Løvås K. Management of endocrine disease: epidemiology, quality of life and complications of primary adrenal insufficiency: a review. Eur J Endocrinol. 2016;175(3):R107-R116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27068688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bornstein SR, Allolio B, Arlt W, et al. . 
Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364-389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4880116</ArticleId>
            <ArticleId IdType="pubmed">26760044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107-113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22776786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shi H, Sheng R, Hu Y, et al. . 
Risk factors for the relapse of Graves’ disease treated with antithyroid drugs: a systematic review and meta-analysis. Clin Ther. 2020;42(4):662-675.e4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32139177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2016;101(4):1381-1389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26863422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tanrikulu S, Erbil Y, Ademoglu E, et al. . 
The predictive value of CTLA-4 and Tg polymorphisms in the recurrence of Graves’ disease after antithyroid withdrawal. Endocrine. 2006;30(3):377-381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17526951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wolff AS, Mitchell AL, Cordell HJ, et al. . 
CTLA-4 as a genetic determinant in autoimmune Addison’s disease. Genes Immun. 2015;16(6):430-436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4561510</ArticleId>
            <ArticleId IdType="pubmed">26204230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Skinningsrud B, Husebye ES, Gervin K, et al. . 
Mutation screening of PTPN22: association of the 1858T-allele with Addison’s disease. Eur J Hum Genet. 2008;16(8):977-982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18301444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Skinningsrud B, Lie BA, Lavant E, et al. . 
Multiple loci in the HLA complex are associated with Addison’s disease. J Clin Endocrinol Metab. 2011;96(10):E1703-E1708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21816777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eriksson D, Røyrvik EC, Aranda-Guillén M, et al. . 
GWAS for autoimmune Addison’s disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nat Commun. 2021;12(1):959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7878795</ArticleId>
            <ArticleId IdType="pubmed">33574239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sjölin G, Holmberg M, Törring O, et al. . 
The long-term outcome of treatment for Graves’ hyperthyroidism. Thyroid. 2019;29(11):1545-1557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31482765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vogt EC, Breivik L, Røyrvik EC, Grytaas M, Husebye ES, Øksnes M. Primary ovarian insufficiency in women with Addison’s disease. J Clin Endocrinol Metab. 2021;106(7):e2656-e2663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8208662</ArticleId>
            <ArticleId IdType="pubmed">33686417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dasari S, Naha K, Hande M, Vivek G. Hot and cold: coexistent Graves’ disease and Hashimoto’s thyroiditis in a patient with Schmidt’s syndrome. BMJ Case Rep. 2014;2014:bcr2013010432.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
